Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Eye disorders – page 7

  • 373 clinical trials
  • 123 recruiting
  • 138 conditions
  • 27 countries

Conditions in this area

138 conditions with trials, the busiest first

Conjunctivitis allergic34Sjogren's syndrome31Endocrine ophthalmopathy26Neovascular age-related macular degeneration23Giant cell arteritis18Seasonal allergy17Uveal melanoma17Dry age-related macular degeneration16Rhinitis allergic16Diabetic retinal oedema13Dry eye12Age-related macular degeneration11Retinitis pigmentosa11Asthma10Graves' disease10Myopia10Glaucoma8Open angle glaucoma8Uveitis8Immunoglobulin G4 related disease7Behcet's syndrome6Cataract6Mite allergy6Neuromyelitis optica spectrum disorder6+114

Clinical trials in Eye disorders

373 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

373 clinical trials

Endocrine ophthalmopathy

Recruiting

Study on Treating Graves' Eye Disease with Diclofenac or Simvastatin for Patients with Mild to Moderate Symptoms

Registered drugNo placebo
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:Simvastatin
  • Sponsor:Region Skane

Neuromyelitis optica spectrum disorder

Recruiting

Study of Satralizumab for Children with Neuromyelitis Optica Spectrum Disorder (NMOSD)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Satralizumab
  • Sponsor:F. Hoffmann-La Roche AG

Conjunctivitis allergic+3

Recruiting

Study on the Effectiveness and Safety of Sublingual MM09 for Patients Aged 12-65 with Allergies to House Dust Mites and Rhinitis/Rhinoconjunctivitis with or without Asthma

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dermatophagoides Farinae Extract
  • Sponsor:Inmunotek S.L.

Rheumatoid arthritis+1

Recruiting

PET/CT Imaging Study for Patients with Giant Cell Arteritis or Rheumatoid Arthritis Using Zirconium (89Zr) Crefmirlimab Berdoxam

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Zirconium (89ZR) crefmirlimab berdoxam
  • Sponsor:Universitair Medisch Centrum Groningen

Neovascular age-related macular degeneration

Recruiting

Study on Long-Term Safety of Ranibizumab for Patients with Wet Age-Related Macular Degeneration Using a Port Delivery System

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:F. Hoffmann-La Roche AG

Retinitis pigmentosa

Recruiting

Study of GS030 gene therapy safety and tolerability in patients with Retinitis Pigmentosa

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adeno-Associated Viral Vector Serotype 2.7M8 Containing The Chrimsonr-Tdtomato Gene
  • Sponsor:Gensight Biologics

Conjunctivitis allergic+3

Recruiting

Study on the Effectiveness and Safety of a Grass and Juniperus Oxycedrus Allergy Vaccine for Patients with Allergic Rhinitis or Rhinoconjunctivitis with or without Mild Asthma

Investigational
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Substances:Allergen Extract From Dactylis Glomerata Pollen, Glutaraldehyde-Modified
  • Sponsor:Inmunotek S.L.

Uveitis+1

Recruiting

Study on the Effectiveness and Safety of Tocilizumab and Adalimumab for Patients with Severe Uveitis in Behçet’s Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Retinoblastoma

Recruiting

Study on Retinoblastoma Treatment Using Etoposide, Carboplatin, and Melphalan for Patients with Specific Eye Conditions

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:Institut Curie

Giant cell arteritis

Recruiting

Study on [18F]Fluoro-PEG-Folate Imaging for Patients with Giant Cell Arteritis

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:[18F]Fluoro-Peg-Folate
  • Sponsor:Universitair Medisch Centrum Groningen

Uveal melanoma

Recruiting

Study of ipilimumab, nivolumab and melphalan combination therapy with hepatic perfusion in patients with advanced uveal melanoma that has spread to other organs

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Leiden University Medical Center

Uveal melanoma

Recruiting

Title: Comparing tebentafusp treatment versus observation in patients with high-risk eye melanoma (uveal melanoma) after initial treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tebentafusp
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Substances studied in this area

The therapies tested most often in Eye disorders trials.

Aflibercept27 clinical trialsSodium Chloride16 clinical trialsPrednisone14 clinical trialsRanibizumab14 clinical trialsDexamethasone11 clinical trialsDexamethasone Phosphate10 clinical trialsFluorescein Sodium10 clinical trialsPrednisolone10 clinical trialsNivolumab8 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.